Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mannkind Corp (NQ: MNKD )

3.500 -0.020 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,919,448
Open 3.520
Bid (Size) 3.460 (14)
Ask (Size) 3.540 (5)
Prev. Close 3.520
Today's Range 3.455 - 3.575
52wk Range 3.375 - 5.750
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MannKind (MNKD) Q3 2023 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
MannKind Corporation Reports 2023 Third Quarter Financial Results
From MannKind
Via GlobeNewswire

Performance

YTD
-32.82%
-32.82%
1 Month
-15.87%
-15.87%
3 Month
-25.05%
-25.05%
6 Month
-16.47%
-16.47%
1 Year
-20.63%
-20.63%

More News

Read More
A Preview Of MannKind's Earnings
Via Benzinga
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
From MannKind
Via GlobeNewswire
Why MannKind Stock Soared 19% Higher on Tuesday
Via The Motley Fool
MannKind (MNKD) Q2 2023 Earnings Call Transcript
Via The Motley Fool
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
From MannKind
Via GlobeNewswire
MannKind Analyst Turns Bullish, Says 'Don't Call It Comeback'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Earnings Preview For MannKind
Via Benzinga
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Via InvestorPlace
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
3 Biotech Stocks to Sell in August Before They Crash and Burn
Via InvestorPlace
Intuit To Rally More Than 20%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
MannKind Corporation Reports 2023 Second Quarter Financial Results
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
From MannKind
Via GlobeNewswire
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
Via InvestorPlace
7 Biotech Stocks to Sell in July
Via InvestorPlace
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
From MannKind
Via GlobeNewswire
7 Overvalued Penny Stocks to Sell Before June 2023
Via InvestorPlace
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
From MannKind
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.